Crossmark

New insights into the role of TREM2 in Alzheimer’s disease

Published Online: 2018-12-20

Published Print: 2018-12

Authors

Gratuze, Maud

Leyns, Cheryl E. G.

Holtzman, David M. http://orcid.org/0000-0002-3400-0856
Funding

Funding for this research was provided by:

Edward N. and Della L. Thome Memorial Foundation (none)
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 25 October 2018

Accepted: 28 November 2018

First Online: 20 December 2018

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: DMH is listed as an inventor on a provisional patent from Washington University on TREM2 antibodies. CEGL and DMH are listed as inventors on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. DMH co-founded and is on the scientific advisory board of C2N Diagnostics, LLC. C2N Diagnostics, LLC has licensed certain anti-tau antibodies to AbbVie for therapeutic development. DMH is on the scientific advisory board of Proclara and Denali and consults for Genentech, AbbVie, and Idorsia.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current